A compact, thermostable platform that enables higher‑capacity intradermal delivery while remaining simple, reliable, and manufacturing‑friendly.
This site is public‑safe and omits proprietary technical details. For specifics, contact us under NDA.
UniDose is a next‑generation intradermal drug delivery platform designed to overcome the limitations of existing microneedle and injection systems. Our protected approach supports significantly higher payload capacity than current solutions while maintaining simplicity, reliability, and patient comfort.
The platform is compact, thermostable, and compatible with established fill‑finish and lyophilization processes, enabling efficient scale‑up. By unlocking intradermal delivery for a broad range of therapeutics—including vaccines and large‑molecule drugs—UniDose aims to improve access, efficacy, and safety worldwide.
No reconstitution; reduced cold‑chain burden.
User‑independent delivery at controlled depth.
Compatible with standard fill‑finish + lyo.
Modular reservoirs for broad therapeutic use.
Biologics and advanced therapeutics often face delivery challenges: variable absorption with subcutaneous injection, inconsistent outcomes with traditional intradermal methods, and manufacturability limits for first‑generation patches.
UniDose is a press‑and‑click intradermal system that ensures consistent placement while remaining patient‑friendly and scalable. In a dry (lyophilized) format, medications can be more thermostable, easing cold‑chain demands and simplifying distribution.
UniDose aligns with proven pharmaceutical workflows. The modular design integrates into existing aseptic fill‑finish and lyophilization processes without costly overhauls.
Public‑health programs where thermostability and ease of use are critical.
Enabling intradermal delivery for large‑molecule therapeutics.
Extensible platform for future modalities as evidence develops.
For detailed technical or strategic information, request an NDA discussion.
Email UniDose